Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Shares Up 8 Percent on Patent News

NEW YORK, Feb. 3 (GenomeWeb News) - Shares in Accelr8 were up 7.95 percent, or $.21, at $2.85 in late-afternoon trading after the company said it won a US patent for its OptiChem surface chemistry.


The stock shot up to $3.35 in early-morning trade before settling down to $2.85 in unusually heavy volume.


The patent, No. 6,844,028, covers a new coating that "makes it possible to selectively capture, target and analyze individual bacteria. ... "


OptiChem is a component of Accelr8 's new BACcelr8r diagnostic system that, "when fully developed, has the potential to replace bacterial culturing by producing test results in a matter of hours," the company said. Results from traditional culturing "typically require several days," Accelr8 said.

Accelr8 currently sells OptiChem-coated slides for research applications, and is developing custom coating formulations for industrial clients.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.